#### Mental health conditions and COVID-19 vaccine outcomes: a scoping review

<sup>1</sup>Ru Jia PhD, <sup>1,2</sup>Carol Coupland PhD, <sup>2</sup>Yana Vinogradova PhD, <sup>2</sup>Nadeem Qureshi PhD, <sup>3</sup>Emma Turner PhD, <sup>4\*</sup>Kavita Vedhara PhD

<sup>1</sup>Nuffield Department of Primary Care Health Sciences, Medical Science Division, University of Oxford, Radcliffe Observatory Quarter, Oxford, OX2 6GG, UK

<sup>2</sup>Centre for Academic Primary Care, Lifespan and Population Health, School of Medicine, University of Nottingham, University Park, Nottingham, NG7 2RD, UK

<sup>3</sup>Bristol Medical School, University of Bristol, Bristol, BS8 1QU, UK

<sup>4</sup>School of Psychology, Cardiff University, Tower Building, Cardiff, CF10 3AT, UK.

\* Author to whom all correspondence should be addressed: Professor Kavita Vedhara, School of Psychology, Cardiff University, Tower Building, Cardiff, CF10 3AT, UK. <u>VedharaK@cardiff.ac.uk</u>

# Mental health conditions and COVID-19 vaccine outcomes: a scoping review Abstract

**Background:** The COVID-19 pandemic has had a profound impact on the mental health of people worldwide. Mental health also impacts on physical health. In the context of viral illnesses, viral challenge studies have shown that indices of mental health are associated with susceptibility to viral infections, including coronaviruses. Research conducted during the pandemic has shown that people with a history of mental health conditions were at increased risk of infection, hospitalisation, and mortality. However, the relationship between mental health conditions and vaccine outcomes such as vaccine intentions, uptake, and vaccine breakthrough is not yet well-understood.

Methods: We conducted a systematic search on the topics of COVID-19 vaccine intentions, vaccine uptake, and vaccine breakthrough, in relation to mental health conditions, in four databases: PubMed, MEDLINE, SCOPUS, and PsychINFO, as well as the publication lists of Clinical Practice Research Datalink (CPRD), The Health Improvement Network (THIN), OpenSAFELY, and QResearch. Inclusion criteria focus on studies reporting either of the aforementioned COVID-19 vaccine outcomes among people with mental health conditions. **Results:** Thirty-three out of 251 publications met our inclusion criteria for this review. Overall, the evidence is inconclusive regarding the level of intention to accept the COVID-19 vaccine among people with mental health conditions. However, people with mental health conditions were more likely to have lower uptake of the COVID-19 vaccine, compared to people without. Common barriers to COVID-19 vaccine uptake include concerns about the safety, effectiveness, and side effects of the vaccines. Limited evidence also suggests that vaccine breakthrough may be a particular risk for those with substance use disorder. **Conclusions:** Our findings revealed a possible intention-behaviour gap for receiving the COVID-19 vaccine among people with mental health conditions, yielding interventions to

encourage vaccine uptake in this population. There is also the need to enhance our

understanding of COVID-19 vaccine breakthrough in people with mental health conditions.

### Keywords: COVID-19, mental health, vaccination

#### Introduction

The COVID-19 pandemic resulted in more than 700 million cases and 6 million deaths globally (WHO, n.d.). Vaccines against SARS-CoV-2 were developed to reduce the spread of the virus and morbidity and mortality caused by COVID-19. The UK was the first country to approve a COVID-19 vaccine and started a vaccine roll-out program in December 2020 (Authority of the House of Commons, 2022). By autumn 2022, approximately 151 million vaccinations were given to the UK population (Majeed et al., 2022). However, while the mass vaccination roll-out was necessary in the pandemic, certain factors determine whether vaccines can realise their full potential. Arguably, the two most salient of these are vaccine uptake i.e., an individual's willingness to be vaccinated and vaccine effectiveness i.e., the ability for vaccines to protect against infection and adverse outcomes.

One factor that may influence both vaccine uptake and vaccine effectiveness is mental health. Pre-pandemic the evidence suggested that people with mental illness might be less likely to engage in preventive healthcare such as blood pressure monitoring and vaccinations, compared with people without mental illness (Lord et al., 2010). Evidence during the pandemic seems to show a mixed picture. For example, a study in early 2021 found higher COVID-19 vaccine uptake (i.e., receiving at least one dose) among people with mood disorders (e.g., major depression and bipolar disorder) in certain areas in the UK, but lower COVID-19 vaccine uptake among individuals with psychotic disorders (e.g., schizophrenia), compared with people without mental illness (Hassan et al., 2022). Another study, conducted in the same year, found that the vaccination rate among people with mental health conditions (11%) was lower than the vaccination rate among other residents (40%) in Wuhan area (Huang et al., 2021). Reviews of the literature on vaccine hesitancy appear to confirm that the relationship between vaccine uptake and mental health varies according to the nature of the mental health problem (Farcas et al., 2022). However, attempts to review and synthesise this evidence have been limited to studies capturing the intention (or not) to be vaccinated, rather than actual uptake.

There is also potential for mental health to influence the effectiveness of COVID-19 vaccines. Mental health can dysregulate the immune system and thus can impair the immune response to vaccination (Cohen, 2021; O'Connor et al., 2021; Vedhara et al., 1999). For example, viral and vaccine challenge studies have shown that depression and stress are associated with poorer antibody responses to vaccinations, as well as increased risk of infection and symptomatic illness (Cohen, 2021; Cohen et al., 1998; Phillips et al., 2006; Vedhara et al., 1999).

Evidence from the pandemic suggests that this relationship between mental health and impaired responses to respiratory infections may also occur in the context of COVID-19. For example, observational data have shown that greater psychological distress was significantly associated with subsequent self-reported SARS-CoV-2 infection, together with an increased number of, and more severe, symptoms (Ayling et al., 2022). Similarly, Yang and colleagues reported that people with previous mental health conditions were more likely to get SARS-CoV-2 infection, be hospitalised, and to die from COVID-19 (Yang et al., 2020). However, no study, to our knowledge, has reviewed current evidence on the association between mental health conditions and COVID-19 vaccine breakthrough (i.e., evidence of SARS-CoV-2 infection after vaccination).

Thus, in summary, there is evidence to suggest that mental health conditions are associated with greater vaccine hesitancy, impaired immune responses to vaccination and greater risk of respiratory infections. In the context of COVID-19, the emerging evidence suggests that the relationship with vaccine hesitancy may vary between different mental health conditions; the relationship with vaccine uptake is less clear and while poorer COVID-19 outcomes have been associated with mental health conditions, the evidence on the relationship with vaccine effectiveness is limited. In an effort to bring this literature together, we present here results from a scoping review in which we have examined the evidence exploring the relationship between indices of mental health (past and current) and vaccine hesitancy (i.e., behavioural intentions), vaccine uptake (behavioural response) and vaccine effectiveness as measured by vaccine breakthrough i.e., evidence of infection following vaccination. An understanding of this literature will help to inform whether and in what ways people with mental health conditions need to be supported to reduce their risk of COVID-19 infection.

#### Methods

#### Population

The population of interest was people with mental health conditions. Consistent with previous work, mental health conditions included depression, anxiety, stress-related disorder, substance misuse, psychotic disorders, schizophrenia, and bipolar disorder (Thompson et al., 2022; Yang et al., 2020). We included studies involving people with a history of mental health difficulties as well as those arising during the pandemic. No restrictions were made for other characteristics, including age, gender, health conditions etc.

#### Outcomes

The outcomes of interest were intention to accept or decline a COVID-19 vaccination when offered, COVID-19 vaccine uptake, and COVID-19 vaccine breakthrough. A COVID-19 vaccine breakthrough infection is defined according to CDC: "the detection of SARS-CoV-2 RNA or antigen in a respiratory specimen collected from a person ≥14 days after receipt of all recommended doses of an FDA-authorized COVID-19 vaccine" (Birhane et al., 2021).

#### Search strategy

Searches for relevant studies were conducted in PubMed, MEDLINE, SCOPUS, and PsychINFO. To include potentially eligible population-based studies, the CPRD, The Health Improvement Network (THIN), OpenSAFELY, and QResearch lists of publications were also searched. To include articles that may be under review, the electronic pre-print service MedRxiv was also searched. The search paradigm was based on the following combination: (*mental, major* [MeSH terms]) AND (*COVID-19 vaccine* [MeSH terms]). To ensure our searches were comprehensive, the term *mental* was replaced with psychiatric, schizophrenia, psychotic, bipolar disorder, mood disorder, major depressive disorder, anxiety disorder, personality disorder, eating disorder, alcohol abuse, alcohol misuse, substance abuse, and substance misuse. We limited our searches to publications in English language. We did not limit the searches by time period.

#### **Eligibility criteria**

Only observational studies were included. Eligible studies had to report at least one of the following: (1) intentions towards COVID-19 vaccine (i.e., intended willingness to accept or decline a vaccination when offered) among people with mental health conditions, and in comparison with people without mental health conditions where applicable; (2) COVID-19 vaccine uptake rate among people with mental health conditions, and in comparison with people without mental health conditions, and in comparison with people with mental health conditions, and in comparison with people without mental health conditions where applicable; (3) COVID-19 vaccine breakthrough (i.e., evidence of SARS-CoV-2 infection after vaccination) among people with mental health conditions. For mixed-method studies, only the observational part of the study was included. Only articles reporting results from original observational studies were included. Qualitative studies, reviews, protocols, commentary or opinion pieces, editorial letters and posters were excluded.

#### **Barriers to COVID-19 vaccine uptake**

We were also interested in the potential predictors to COVID-19 vaccine intention, and vaccine uptake. However, predictors of COVID-19 vaccine intention have been systematically reviewed in previous work (see Farcas et al., 2022; Terry et al., 2022; Q. Wang et al., 2021). Demographic predictors (e.g., age, gender, ethnicity, education, socioeconomic status, etc) of vaccine uptake in general have also been reviewed previously (see Galanis et al., 2021). Therefore, in the current review, where studies reported on psychological barriers to COVID-19 vaccine uptake (e.g., beliefs, trust, etc.), we summarised these findings.

#### Results

#### **Selection of studies**

The database search was conducted on 9<sup>th</sup> November 2022 and returned 251 initial results. Of these, 197 studies were excluded after title and abstract screening and 21 studies were excluded after full-text screening (Figure 1). The main reasons for exclusion include the article being a comment piece or review of literature or intervention etc. (k=51, 23%); studies not conducted among people with mental health conditions (k=42, 28%), and not investigating the outcomes of interest (k=16, 8%). Therefore, 33 studies were included in this scoping review.




Figure 1 Flow diagram for the scoping review

#### **Overview of study characteristics**

The 33 studies included in this review were conducted across 13 countries and regions including North America (e.g., Canada and the United States), Europe (e.g., United Kingdom, Belgium, France, Denmark), Asia (e.g., Mainland China, Japan, India, Taiwan), and the Middle East (e.g., Israel and Qatar). Of the 33 studies, 22 used survey designs including 6 longitudinal survey studies. Ten studies collected data from electronic health or registration records, including one study linking survey and electronic health record data. Two studies

examined vaccine outcomes among patients within psychiatric hospitals through healthcare screening and assessment. Populations investigated by these studies included the general public or population-representative cohorts, and more specific cohorts for instance veterans, psychiatric patients, adolescents with attention-deficit/hyperactivity disorder (ADHD), and youth who are 2-spirit, lesbian, gay, bisexual, transgender, queer, and questioning (2SLGBTQ+) and experiencing homelessness, etc. One study investigated the intentions to vaccinate children with ADHD among their caregivers (Tsai et al., 2022). The sizes of the studies range from 62 to 57.9 million.

#### **Measurement of mental health conditions**

Twenty-one of the 33 reviewed studies identified patients with mental health conditions through clinical diagnoses obtained from medical records (Bai et al., 2021; Cai et al., 2022; Curtis, Inglesby, MacKenna, et al., 2022; Curtis, Inglesby, Morton, et al., 2022; Eyllon et al., 2022; Gibbon et al., 2021; Hassan et al., 2022; Jefsen et al., 2021; Mazereel et al., 2021; Moeller et al., 2021; Nilsson et al., 2022; Nishimi, Neylan, et al., 2022; Qin et al., 2022; Raffard et al., 2022; Ren et al., 2021; Shkalim Zemer et al., 2022; Sullivan et al., 2022; Tsai et al., 2022; Tzur Bitan et al., 2022; Uvais, 2022; L. Wang et al., 2022).

The recorded mental health conditions included depressive disorder, bipolar disorder, schizophrenia, ADHD, PTSD, generalized anxiety disorder, and substance use disorder, etc. One study used records of prescription of psychotropic drugs (i.e., anxiolytics, antipsychotics, hypnotics, and antidepressants) as an indication of patients' mental health conditions (Murphy et al., 2022). Six studies asked participants to self-report whether they have been diagnosed with mental health conditions (Afifi et al., 2021; Balut et al., 2021; Dvorsky et al., 2022; Huang et al., 2021; Paul & Fancourt, 2022; Roberts et al., 2022). Five other studies measured self-reported anxiety, depression, substance use, and posttraumatic stress disorder

(PTSD) through surveys such as the Physician Health Questionnaire (PHQ-9, Kroenke et al., 2010), the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7, Spitzer et al., 2006), and the 20-item posttraumatic stress disorder Checklist-5 (PCL-5, Blevins et al., 2015; Abramovich et al., 2022; Khaled et al., 2021; Nguyen et al., 2022; Nishimi et al., 2022; Sekizawa et al., 2022).

#### Mental health conditions and COVID-19 vaccine intentions

Eighteen of the 33 reviewed studies reported on the association between the presence of mental health conditions and willingness or hesitancy to accept the COVID-19 vaccine or booster vaccine (Abramovich et al., 2022; Afifi et al., 2021; Bai et al., 2021; Cai et al., 2022; Dvorsky et al., 2022; Eyllon et al., 2022; Huang et al., 2021; Jefsen et al., 2021; Khaled et al., 2021; Nguyen et al., 2022; Nishimi, Borsari, et al., 2022; Paul & Fancourt, 2022; Qin et al., 2022; Ren et al., 2021; Roberts et al., 2022; Sekizawa et al., 2022; Sullivan et al., 2022; Tsai et al., 2022). The sizes of the studies range from 92 to 77104 (see Table 1). Participants in these studies were asked to indicate their intentions once the COVID-19 vaccines became available. Seventeen of the 18 studies reported on people with current mental health conditions. In the remaining study, no distinction was made between current and history of mental health conditions (Roberts et al., 2022). Therefore, we do not distinguish between current and history of mental health conditions in the following reporting.

Across the 18 studies, the intended willingness to accept a COVID-19 vaccination was between 44% and 93% among people with mental health conditions.

#### Differences between people with and without mental health conditions

When compared with people without mental health conditions, the majority of studies (i.e., 12/18) found no differences in vaccine hesitancy between people with and without mental health conditions. Specifically, 5/18 studies reported that people with mental health

conditions were less willing or more hesitant to accept the COVID-19 vaccine. In general, the degree of hesitancy varied significantly between the studies with rates of hesitancy as low as 15.2% through to 53% (Abramovich et al., 2022; Dvorsky et al., 2022; Eyllon et al., 2022; Jefsen et al., 2021; Sekizawa et al., 2022). Three out of the five studies reported that the levels of hesitancy were significantly higher in patients with mental health conditions including major depressive disorder, bipolar disorder, anxiety disorder, ADHD, PTSD, substance use disorder (0.78-2.74 times, Abramovich et al., 2022; 0.65-1.68 times, Eyllon et al., 2022; 4.7%, Jefsen et al., 2021). Only 1/18 studies reported the contrary: individuals with anxiety or depression were 1.13 times (95% CI: 1.08-1.19) more likely to intend to get a vaccine than those without these conditions (Nguyen et al., 2022). Six of the 18 studies found no differences in vaccine hesitancy between people with and without mental health conditions. Specifically, one reported that having depression or anxiety symptoms was not associated with willingness to have a COVID-19 vaccine (Khaled et al., 2021). One reported that having a mental health condition was not associated with uncertainty or unwillingness to accept a COVID-19 booster vaccine (Paul & Fancourt, 2022). One reported that PTSD symptom clusters were not associated with COVID-19 vaccine hesitancy in the investigated cohort (Nishimi, Borsari, et al., 2022). The other three of the nine studies reported similar levels of willingness to accept a COVID-19 vaccine between participants with and without mental health conditions (Afifi et al., 2021; Mazereel et al., 2021; Roberts et al., 2022).

#### Differences between different mental health conditions

Three of the 18 studies reported findings in relation to patients' different diagnosis and treatment conditions. Bai et al., (2021) did not find any significant difference in vaccine hesitancy across major depressive disorder, bipolar disorder, and schizophrenia. However, they reported that community-dwelling psychiatric patients had a higher incidence of COVID-19 vaccination hesitancy (49%) compared to hospitalised patients (31%). Mazereel

et al., (2021) also reported no effect of different psychiatric diagnosis on vaccine acceptance. Eyllon et al., (2022) reported that, after adjusting for other sociodemographic characteristics and physical comorbidities, patients with substance use disorders had 68% higher odds for vaccine hesitancy while bipolar disorder was associated with 35% lower odds for vaccine hesitancy.

Overall, these findings suggest that most studies fail to find evidence of significantly greater hesitancy in people with mental health conditions, with only five studies reporting greater hesitancy among people with mental health conditions. The evidence on the association between different mental health diagnosis and vaccine intentions is limited and, therefore, not conclusive. The available evidence suggests that patients with substance use disorder might have higher risks of COVID-19 vaccine hesitancy, compared with other mental health conditions.

#### Mental health conditions and COVID-19 vaccine uptake

Seventeen of the 33 reviewed studies reported on the association between mental health conditions and the uptake of the COVID-19 vaccine or booster vaccine (Table 2, Balut et al., 2021; Curtis, Inglesby, MacKenna, et al., 2022; Curtis, Inglesby, Morton, et al., 2022; Gibbon et al., 2021; Hassan et al., 2022; Huang et al., 2021; Mazereel et al., 2021; Moeller et al., 2021; Murphy et al., 2022; Nguyen et al., 2022; Nilsson et al., 2022; Qin et al., 2022; Raffard et al., 2022; Sekizawa et al., 2022; Shkalim Zemer et al., 2022; Tzur Bitan et al., 2022; Uvais, 2022). Sizes of the studies ranged from N=62 to 57.9 million. Nine of the 17 studies measured COVID-19 vaccine uptake using participants' health or medical records (Balut et al., 2021; Curtis, Inglesby, MacKenna, et al., 2022; Curtis, Inglesby, Morton, et al., 2022; Hassan et al., 2022; Moeller et al., 2021; Murphy et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2021; Curtis, Inglesby, Morton, et al., 2022; Curtis, Inglesby, Morton, et al., 2022; Hassan et al., 2022; Tzur Bitan et al., 2021; Murphy et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Nilsson et al., 2022; Nilsson et al., 2022; Nilsson et al., 2022; Nilsson et al., 2022; Curtis, Inglesby, Morton, et al., 2022; Hassan et al., 2022; Tzur Bitan et al., 2021; Murphy et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Nilsson et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Tzur Bitan et al., 2021; Murphy et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Tzur Bitan et al., 2022; Nilsson et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Tzur Bitan et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Tzur Bitan et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Tzur Bitan et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Tzur Bitan et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Tzur Bitan et al., 2022; Nilsson et al., 2022;

to self-report their vaccine status (Huang et al., 2021; Nguyen et al., 2022; Raffard et al., 2022; Sekizawa et al., 2022; Uvais, 2022), and two of the 17 studies recorded the number of patients in hospital accepting the COVID-19 vaccine when offered (Gibbon et al., 2021; Mazereel et al., 2021). One of the 17 studies did not clearly describe how vaccine uptake was measured (Qin et al., 2022). 13 of the 17 studies reported on people with current mental health conditions (Balut et al., 2021; Gibbon et al., 2021; Huang et al., 2021; Mazereel et al., 2021; Moeller et al., 2021; Murphy et al., 2022; Nguyen et al., 2022; Qin et al., 2022; Raffard et al., 2022; Sekizawa et al., 2022; Shkalim Zemer et al., 2022; Tzur Bitan et al., 2022; Uvais, 2022). Four of the 17 studies reported on people with either current or history of mental health conditions, but no distinction was made between current and history of mental health conditions (Curtis, Inglesby, MacKenna, et al., 2022; Curtis, Inglesby, Morton, et al., 2022; Hassan et al., 2022; Nilsson et al., 2022). Therefore, we did not distinguish between current and history of mental health conditions in the following reporting.

In the 17 studies, the reported uptake of COVID-19 vaccines (including boosters) ranged from 2% to 93%, among patients with mental health conditions. One study was conducted early in the pandemic when the COVID-19 vaccines were not widely available (October 2020 – May 2021), thus their reported COVID-19 vaccine uptake rates were low (2-3%, Sekizawa et al., 2022). After excluding this study, other studies reported an uptake of 11-93% among patient with mental health conditions.

#### Differences between people with and without mental health conditions

Thirteen of the 17 studies compared COVID-19 vaccine uptake among people with mental health conditions with uptake among people without these conditions. Eight of these 13 studies observed that uptake was lower in people with mental health conditions (Curtis, Inglesby, MacKenna, et al., 2022; Curtis, Inglesby, Morton, et al., 2022; Murphy et al., 2022;

Nguyen et al., 2022; Nilsson et al., 2022; Qin et al., 2022; Raffard et al., 2022; Tzur Bitan et al., 2022). The reported vaccine uptake was between 3-21% lower among people with mental health conditions. Five of the 13 studies observed that the vaccine uptake was up to 1.19 times higher among patients with mental health conditions, compared with people without (Balut et al., 2021; Hassan et al., 2022; Mazereel et al., 2021; Moeller et al., 2021; Shkalim Zemer et al., 2022). However, among these five studies, two further reported significantly higher rates of declining the COVID-19 primary or booster vaccines among people with mental health conditions, compared with people without (Hassan et al., 2022; Shkalim Zemer et al., 2022). Two of the 17 studies reported the uptake of booster vaccines. Shkalim Zemer et al., (2022) reported higher uptake of the booster vaccine among adolescents with ADHD aged 16-17 (46%) compared with non-ADHD adolescents of the same age (43%), and similar uptake of the booster vaccine among adolescents with ADHD agolescents of the same age (1.2% vs 1.4%). Tzur Bitan et al., (2022) reported significantly lower booster vaccine uptake among patients with schizophrenia (75%) compared with people without (78%).

#### Differences between different mental health conditions

Two of the 17 studies compared vaccine uptake across different psychiatric diagnoses but reported different observations. One reported that 51% of patients with schizophrenia were vaccinated, which was lower (significance levels unreported) than those with other psychiatric disorders: bipolar disorder, 74%; depression disorder, 74%; anxiety disorder, 66%; obsessive-compulsory disorder, 85%; sleep disorder, 80%; other psychiatric disorders, 65% (Qin et al., 2022). Another study, however, did not find significant effects of psychiatric diagnosis on vaccine uptake (Mazereel et al., 2021).

#### Barriers to COVID-19 vaccine uptake among people with mental health conditions

We also extracted results on barriers to the COVID-19 vaccine uptake among people with mental health conditions from these studies. Five of the 17 studies reported results on this (Huang et al., 2021; Nguyen et al., 2022; Qin et al., 2022; Raffard et al., 2022; Uvais, 2022). Four of the five studies reported that, among people with mental health conditions, unvaccinated individuals were more likely to report greater concerns about the safety, effectiveness, and side effects of the COVID-19 vaccine than vaccinated people (Huang et al., 2021; Nguyen et al., 2022; Raffard et al., 2022; Uvais, 2022). Lack of trust in the vaccine, development of the vaccine, and the government was reported among unvaccinated people with mental health conditions in two studies (Nguyen et al., 2022; Raffard et al., 2022). One study reported that the vaccination rate was higher among patients who had the intention to be vaccinated (78%), compared with those who were unwilling to be vaccinated (21%) or those who were uncertain about the vaccination (13%, Qin et al., 2022). One study reported that recommendation for vaccination from health care providers was positively associated with vaccine uptake in people with mental health conditions (Uvais, 2022).

Overall, the observed uptake of COVID-19 vaccines among people with mental health conditions varied between studies. The results were mixed, with 8/13 studies reporting lower vaccine uptake in people with mental health conditions and 5/13 studies reporting no differences. Although with limited evidence, patients with schizophrenia might have lower COVID-19 vaccine uptake, compared with people without mental health conditions and people with other mental health conditions. Among people with mental health conditions, the most common barriers to COVID-19 vaccine uptake include concerns about the safety, effectiveness, and side effects of the COVID-19 vaccine.

#### Mental health conditions and COVID-19 vaccine breakthrough

Only two out of 33 studies reported outcomes related to breakthrough infection following vaccination in people with mental health conditions (Table 3, Nishimi, Neylan, et al., 2022; Wang et al., 2022). Both studies defined a COVID-19 vaccine breakthrough infection as "a positive SARS-CoV-2 test record occurring in the medical records  $\geq 14$  days after their final SARS-CoV-2 vaccine dose", in line with the CDC definition (Birhane et al., 2021). Wang et al., (2022) included patients with current substance use disorders, while Nishimi, Neylan, et al., (2022) included patients who had psychiatric disorder diagnoses within the past five years. The observation period was from February 2020 to November 2021 in Nishimi, Neylan, et al., (2022), and from December 2020 to August 2021 in Wang et al. (2022).

Both studies reported that people with mental health conditions were at increased risk of breakthrough infections for COVID-19. Specifically, Nishimi, Neylan, et al., (2022) reported that patients with any psychiatric disorder were 7% more likely to experience a breakthrough infection (95% CI, 1.05-1.09;  $P \square < \square$ .001), compared with patients without psychiatric disorders, after adjusting for potential confounders (e.g., age, ethnicity, vaccine type, time since vaccine, etc.). These patients were still at 3% increased risk of experiencing breakthrough infection (95% CI, 1.01-1.05;  $P \square < \square$ .001), compared with patients without psychiatric disorders, after further adjusting for medical comorbidities (e.g., diabetes, cardiovascular diseases etc.) and smoking status. Nishimi, Neylan, et al., (2022) also reported that when considering specific psychiatric disorder diagnoses (i.e., major depressive disorder, PTSD, anxiety disorder, adjustment disorder, alcohol use disorder, substance use disorder, bipolar disorder (relative risk=1.13; 95% CI: 1.10-1.16,  $P \square < \square$ .001) and substance use disorders (relative risk=1.16; 95% CI: 1.12-1.21,  $P \square < \square$ .001), after adjusting for

confounders, medical comorbidities, and smoking status and there were no significant increases for psychotic disorder (relative risk=1.05; 95% CI, 0.99-1.11;  $P \square = \square .09$ ).

The other study, Wang et al., (2022), reported that among patients with substance use disorders, the risks for breakthrough infections were 7% for tobacco use, 7% for opioid use, 7 % for alcohol use, 8% for cocaine use, and 8% for cannabis use, all significantly higher than that in matched cohorts without substance use disorder (2-4%, P<0.001). The modest but higher risks of breakthrough infection among patients with substance use disorder remained significant after controlling for age, gender, ethnicity and vaccine types, for all but tobacco use disorder. However, after controlling for socioeconomic determinants of health (e.g., problems related to education, employment, occupational risk factors, and housing and economic circumstances) and physical comorbidities, the risks for breakthrough infection no longer differed between patient with substance use disorder and matched cohorts for all but cannabis use disorder. Patients with cannabis use disorder remained at increased risk (hazard ratio=1.55, 95% CI: 1.22-1.99) compared with matched cohorts without cannabis use disorder. When looking at severe outcomes of vaccine breakthrough infections (i.e., COVID-19 hospitalisation and death), the risk of hospitalization was 22.5% for patients with substance use disorders who experienced breakthrough infections and 1.6% for patients without breakthrough infections. The risk of death was 1.7% for patients with substance use disorders who experienced breakthrough infections and 0.5% respectively. When looking at the type of vaccines patients with substance use received, the risk for breakthrough infection was higher in patients who received the Pfizer than the Moderna vaccine (hazard ratio=1.49, 95% CI: 1.31-1.69).

Findings from these two studies suggest that patients with mental health conditions, especially those with substance use disorder, might be at a slightly increased risk of experiencing breakthrough infection after being vaccinated against COVID-19.

#### Discussion

This review highlights the evidence and gaps in research concerning mental health conditions and three COVID-19 vaccine outcomes: vaccine intentions, vaccine uptake, and breakthrough infection. Overall, the evidence was mixed regarding the level of intention to accept the COVID-19 vaccine among individuals with mental health conditions, compared with those without. This finding largely agrees with previous reviews, where a scarcity of evidence of vaccine hesitancy among people with mental health conditions was reported (Kafadar et al., 2022; Payberah et al., 2022). This is possibly due to the levels of vaccine hesitancy or willingness varying across different mental health conditions, which was not considered in previous reviews. In this scoping review, we further differentiated the levels of vaccine hesitancy between different mental health conditions. We found evidence reporting that patients with substance use disorders had higher odds for vaccine hesitancy, while patients with bipolar disorder had lower odds for vaccine hesitancy (Eyllon et al., 2022). Another study included in this review also reported that community-dwelling patients had a higher proportion of COVID-19 vaccination hesitancy compared to hospitalised patients (Bai et al., 2021). Therefore, combining people with different mental health conditions, or combining hospitalised patients and community-dwelling patients together in such investigations might lead to different results. Future research should divide patients into subgroups of different mental health conditions or diagnoses to understand the association between different conditions or diagnoses and vaccine willingness and hesitancy.

#### Intention versus behaviour

One unique contribution of this review is that we also summarised evidence on the actual uptake of COVID-19 vaccines among people with mental health conditions, and did not rely on data on vaccine intentions. One of the reviewed studies reported results on the intentionbehaviour association: the vaccination rate was higher among patients who were willing to be vaccinated compared with those who were unwilling or uncertain about the vaccination. This result implies that vaccine hesitancy (intention) is a valuable target for interventions to address low vaccine uptake. However, although tackling vaccine hesitancy among people with mental health conditions is important, it might not be sufficient to encourage vaccine uptake in this population. According to the Theory of Planned Behaviour (TPB), attitude towards the behaviour, subjective norm, and perceived behavioural control are three determinants of a behavioural intention, which then lead to a behaviour. The behavioural intention is an "immediate antecedent of behaviour" (Ajzen & Manstead, 2007). Therefore, although intention is a key contributor to behaviour, it might not necessarily translate into a certain behaviour directly. A meta-analysis on the efficacy of TPB examined to what extent behavioural intentions predicted actual behaviours (Armitage & Conner, 2001). They reported that, intention accounted for only 25% variance in behaviours, and the correlation between intention and behaviour was 0.47. This intention-behaviour discordance has been reported in previous literature and in other contexts. For example, a meta-analysis focusing on physical activity found that 36% of people who intended to engage in physical activity failed to do so (Rhodes & de Bruijn, 2013). In a more recent study where TPB was used as the theoretical model to explore the associations between intention and the behaviour of receiving Human papillomavirus (HPV) vaccines using TPB, intention accounted only for 9.6% of the variance in behaviour, while moral norm (i.e., the perceived moral correctness of a behaviour) and intention together accounted for 14.1% of the variances in behaviour (Juraskova et al., 2012).

In the context of vaccine hesitancy, it was also pointed out in literature that there might be circumstances where vaccine hesitancy is not the sole or main contributor to low vaccine uptake (MacDonald, 2015). In this review, the evidence on COVID-19 vaccine intentions and uptake among people with mental health conditions also seems to suggest a discordance between the two. Although the reported uptake of the COVID-19 vaccine varied across studies, depending on the timings, settings, and populations under investigation, most of the studies suggested that people with mental health conditions were more likely to decline the vaccine when offered. Especially when looking at studies (k=8 of 17) using electronic health records with large sample sizes (n>4000), the reported rate of COVID-19 vaccine uptake among people with mental health conditions ranged from 47% to 90% (Balut et al., 2021; Curtis, Inglesby, MacKenna, et al., 2022; Curtis, Inglesby, Morton, et al., 2022; Hassan et al., 2022; Murphy et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Tzur Bitan et al., 2022). Five out of these eight studies reported that people with mental health conditions had significantly lower uptake of the COVID-19 vaccine, compared with people without mental health conditions (Curtis, Inglesby, MacKenna, et al., 2022; Curtis, Inglesby, Morton, et al., 2022; Murphy et al., 2022; Nilsson et al., 2022; Shkalim Zemer et al., 2022; Tzur Bitan et al., 2022), while three reported the opposite (Balut et al., 2021; Hassan et al., 2022; Shkalim Zemer et al., 2022). The nature of this intention-behaviour gap, and other barriers (e.g., other systematic-level barriers) that contribute to low vaccine uptake, need further understanding. Interventions targeting at other aspects of vaccine delivery may also be considered, for example, making vaccines available at psychiatric clinics, providing psychiatrists with sufficient information about the vaccines, providing more support for patients with mental health conditions to receive vaccines at GPs, having engagement campaigns and activities

tailoring to people with mental health conditions and their carers, etc (Mazereel et al., 2021; Payberah et al., 2022).

# Understanding barriers to vaccine hesitancy and uptake in people with mental health conditions

According to the WHO's "3Cs" model of vaccine hesitancy, confidence, complacency, and convenience are the three main determinants of vaccine hesitancy (Sage Working Group on Vaccine Hesitanc, 2014). The "confidence" element mainly includes trusts in the vaccines (e.g., safety, effectiveness, the delivery system, the government, etc.). The "complacency" element mainly includes the perceived risks of vaccine-preventable diseases. Both the "confidence" and "complacency" elements reflect more on the individual-level barriers. The "convenience", on the other hand, mainly reflects systematic-level barriers around the availability, affordability, and accessibility of the vaccine and vaccine services. Both individual-level barriers and system-level barriers may contribute to the lower vaccine uptake in people with mental health conditions (Warren et al., 2021). We also summarised findings regarding these barriers. Our findings suggest that people with mental health conditions are more likely to experience barriers related to the "confidence" (i.e., concerns about the safety, effectiveness, and side effects of the COVID-19 vaccine) and "convenience" (e.g., whether people with mental health conditions received recommendations from health care providers) of the COVID-19 vaccines. These findings suggest studies and interventions should aim to tackle both the individual-level and system-level barriers, especially targeting vaccine "confidence" and "convenience", to encourage the uptake of vaccines in people with mental health conditions. For example, outreach by mental health care providers may be a strategy to improve COVID-19 vaccine uptake in this population. A pilot trial found that when psychiatric providers were actively engaged in addressing concerns about the COVID-19 vaccine with patients with severe mental illness during outpatient visits, the vaccination rate

among outpatients was higher (84%) than estimated (62.1% - 77.3%; Lim et al., 2022). Other strategies such as identifying leaders in the communities to promote vaccination outreach (Sullivan et al., 2022), transparent communication concerning the safety and effectiveness of the COVID-19 vaccines (Eyllon et al., 2022; Jefsen et al., 2021; Sullivan et al., 2022) may also be helpful. Another observation from this review was that, two of the five studies reporting higher or comparable vaccine uptake in people with mental health conditions were conducted among adolescents or children (Moeller et al., 2021; Shkalim Zemer et al., 2022), while all other studies were conducted in adult populations. It is possible that their caregivers' opinions determined vaccine uptake in this group (Shkalim Zemer et al., 2022). Caregiver-related barriers and facilitators to vaccine uptake should also be considered in future studies investigating vaccine uptake in people, especially children or adolescents, with mental health conditions.

#### Vaccine breakthrough in people with mental health conditions

Another contribution of this review is the summary on the association between mental health conditions and COVID-19 vaccine breakthrough. Only two published studies were identified and they both suggested that vaccine breakthrough may be a particular risk for those with substance use disorder (Nishimi, Neylan, et al., 2022; L. Wang et al., 2022). Wang et al. (2022) further reported that these patients were also at risk of more adverse outcomes, including hospitalisation and death, following a breakthrough infection, compared with non-breakthrough infections. These results suggest that psychological stressors may influence the susceptibility to COVID-19. However, both studies were conducted in the US. There is no other evidence that can support generalisability of these findings in other countries and populations. In general, findings from both studies echo evidence from prior to the COVID-19 pandemic that both psychological and social factors affect vulnerability to viral infections and also vaccine effectiveness. For example, the series of viral challenge studies by Sheldon

Cohen and colleagues, where they found that individuals with higher levels of psychological stress or experiencing chronic stressors were at significantly increased risk of acute infectious respiratory illness when exposed to respiratory viruses (e.g., rhinovirus type 2, 9, or 14, respiratory syncytial virus, coronavirus type 229E, rhinovirus RV39, Hanks; Cohen et al., 1991, 1998). Other observational and interventional studies have also shown a consistent pattern in which poorer mental health (e.g., exposure to more stressful life events, bereavement, chronic stress) is associated with sub-optimal vaccine responses (Gallagher et al., 2008; Phillips et al., 2006; Vedhara et al., 1999). The evidence together shows that mental health is associated with an increased risk of illness from viral infection, and increased risk of impaired protection following vaccination over time. This again emphasises the need to encourage people with mental health conditions to receive vaccinations to protect them from increased risks of infections and subsequent illnesses. However, there is need to investigate the risks of vaccine breakthrough in people with mental health conditions in other countries or regions, to allow comparison of the impact of different healthcare systems.

#### Limitations

This scoping review did not assess the quality of the studies or quantitatively assess the relationships between mental health and COVID-19 vaccine outcomes using meta-analysis. For studies concerning COVID-19 vaccine willingness or hesitancy, settings (e.g., in hospital or in community) and populations varied between studies which may limit the generalisability of the findings. In addition, 90% of these studies measured vaccine willingness or hesitancy using different self-reported item(s) where self-report biases may be present (Johnson & Fendrich, 2005). For studies concerning COVID-19 vaccine uptake and breakthrough, studies did not distinguish between people who were experiencing current mental health conditions and who had previous mental health diagnosis. It is unclear whether current or previous mental health conditions would have any impact on vaccine uptake or

breakthrough. Only two studies reported results concerning COVID-19 vaccine breakthrough among people with mental health conditions, suggesting that evidence on this topic is currently limited.

#### **Future directions**

Urgent research effort is needed to investigate the risks of COVID-19 vaccine breakthrough and severe COVID-19 outcomes among people with mental health conditions, and associated risk factors. Future studies should also be encouraged to distinguish between the different mental health conditions and also the impact of current or previous mental health conditions on COVID-19 vaccine outcomes. The nature of barriers to vaccine uptake, and the intentionbehaviour gap in vaccinations also need further investigation.

#### Conclusions

This is the first review, to our knowledge, focusing on the three COVID-19 vaccine outcomes (i.e., intention, uptake, and vaccine breakthrough) among people with mental health conditions. We found that the evidence regarding the level of vaccine intentions in this population was inconclusive. However, the majority of evidence seemed to suggest that the level of vaccine uptake among people with mental health conditions was lower than people without. There might be an intention-behaviour gap among people with mental health conditions, in the context of COVID-19 vaccination. Future studies may investigate both the nature of this intention-behaviour gap, and strategies to encourage vaccine uptake in this population. Limited evidence seemed to also suggest that people with mental health conditions may be at increased risk of COVID-19 vaccine breakthrough. Future work may also investigate the scale of this issue, and possible consequences.

#### Funding

This work was supported by the National Institute for Health Research School for Primary Care Research (NIHR SPCR) [Grant Reference Number: C044, 615]. RJ acknowledges the financial support of the National Institute for Health and Care Research (NIHR) Oxford Health Biomedical Research Centre (BRC). CC acknowledges support from the NIHR Nottingham Biomedical Research Centre. This manuscript reflects preliminary work relating to UK Longitudinal Linkage Collaboration (UK LLC) project LLC\_0027 and UK LLC funding from the UKRI funded Longitudinal Health and Wellbeing National Core Study led by University College London (Grant code MC\_PC\_20059); and UK LLC's UKRI core funding (MR/X021556/1 and ES/X000567/1) supported ET's contribution. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. No other funding supported the work described in this manuscript.

#### **Conflict of interest**

None.

## Table 1 Summary of studies investigating the association between mental health conditions and COVID-19 vaccine intention

Author	Region	Data	Population	Size	Mental	Mental health	Vaccine intention measure	Results
		source			health	condition		
					measure			
Abramovic	Canada	Survey	2SLGBTQ+	92	Self-reported	Anxiety,	"Do you plan on receiving the	Participants who scored
h et al.			youth (average		survey	depression,	COVID-19 vaccine?" (Yes or	mild/moderate or
(2022)			age = 20 years)			substance use	have already received	moderately severe/severe
			experiencing				it/No/Unsure)	on the PHQ-9 depression
			homelessness.					scale had less confidence
			The majority were					in the COVID-19 vaccine
			White 61% (n =					compared to those with
			56); identified					minimal depression.
			their gender					Those with
			identity as					moderate/severe anxiety
			transgender or					had more confidence in
			gender diverse (n					the COVID-19 vaccines
			= 53; ~58%); and					compared to those with
			their sexual					mild/moderate anxiety.

			orientation as					Participants who scored
			bisexual or					in the range of
			pansexual (n =					problematic substance
			40; ~ 43%).					use had less confidence
								in the COVID-19 vaccine
								compared to those
								scoring in the
								nonproblematic
								substance use range.
Afifi et al.	Canada	Longitudin	Young people	1000 at	Self-reported	Mental health	"If a COVID-19 vaccine was	Having a mental health
(2021)		al survey	between the age	baseline	current	conditions	available would you get it?"	conditions were not
			of 14-17 years	(2016-2017),	mental health	included	(Yes/No/Maybe/I don't know)	related to willingness to
			(male=45%,	747 at wave	conditions	depression,		get a COVID-19 vaccine.
			female=55%).	2 (2019) and	"Do you	bipolar disorder,		Among people reporting
				664 in wave	currently	anxiety disorder,		having current mental
				3 (664)	have a long-	obsessive-		health conditions,
					term health	compulsive		willingness to get a
					condition	disorder,		COVID-19 vaccine were:
					that is	posttraumatic		67% yes, 9% no, 25%

					expected to	stress disorder,		unsure. Among those
					last or has	attention-		without current mental
					lasted 6	deficit/hyperactivi		health conditions,
					months or	ty disorder, eating		willingness were 65%
					more and has	disorder, alcohol		yes, 9% no, 26% unsure.
					been	problems, drug		
					diagnosed by	problems,		
					a medical	oppositional		
					doctor or	defiant disorder,		
					other health	and conduct		
					care	disorder.		
					professional?			
					"			
Bai et al.	Mainlan	Survey	Community-	1853 (27%	Clinical	Major depressive	"Do you intend to be	The proportion of
(2021)	d China		dwelling and	male)	diagnosis	disorder (MDD),	vaccinated against COVID-19	COVID-19 vaccination
			hospitalised		according to	bipolar disorder	in the future?" (No/Not having	hesitancy was 45.3%,
			patients with		the	(BD), and	vaccination temporarily/Yes)	with 45.3% in major
			severe mental		International	schizophrenia		depressive disorder,
			illness		Classificatio	(SCZ)		43.6% in bipolar

					n of			disorder, and 47.4% in
					Diseases,			schizophrenia subgroups.
					Tenth			The proportion of
					Revision			COVID-19 vaccination
					(ICD-10),			hesitancy was 49.2% in
					obtained			community-dwelling
					from medical			patients, and 31.3% in
					records			hospitalized patients. No
								significant difference in
								vaccine hesitancy was
								found across the three
								major psychiatric
								disorders.
Cai et al.,	Mainlan	Survey	Patient with	1149	Clinical	Depressive	"Do you intend to be	A total of 617 depressed
(2022)	d China		depression	(male=842,	diagnosis	disorder	vaccinated against COVID-19	patients (53.7%) reported
				female=307)	according to		in the future?" ("I would be	they would accept a
					the		vaccinated against COVID-	future COVID-19
					International		19"/ "I would not accept	vaccination while 435
					Classificatio		COVID-19 vaccination	patients (37.9%) reported

					n of		temporarily"/ "I would refuse	they would not accept
					Diseases,		to accept a COVID-19	COVID-19 vaccination
					Tenth		vaccination")	temporarily, and 97
					Revision			patients (8.4%) stated
					(ICD-10),			they would refuse to
					obtained			accept a COVID-19
					from medical			vaccination.
					records			
Dvorsky et	US	Survey	Adolescents in	196	Self-reported	Attention-	"If a vaccine that could prevent	Only 61.8% of
al. (2022)			11th and 12th	(male=87,	clinical	deficit/hyperactivi	COVID-19 were made	adolescents with ADHD
			grade	mean	diagnosis	ty disorder	available to you, would you	reported vaccine
				age=17.5)		(ADHD)	accept it for yourself?"	acceptance, compared to
							(No/Maybe/Yes/Already	81.3% of adolescents
							vaccinated)	without ADHD.
								Adolescents with ADHD
								were significantly less
								likely to report intent to
								accept the COVID-19
								vaccine, than adolescents

								without ADHD.
Eyllon et	US	Survey and	Patients registered	14365	Clinical	Major depressive	Participants were asked if they	Vaccine hesitancy was
al. (2022)		electronic	at a group	(male=38%,	diagnosis	disorder,	had received at least one dose	significantly more
		health	medical practice	female=63%	according to	generalized	of a COVID-19 vaccine. For	prevalent among
		record		)	the	anxiety disorder,	those who had not yet received	participants with
					International	other anxiety	a vaccine, they were asked	substance use (29.6%),
					Classificatio	disorders,	about their intention to be	attention deficit and
					n of	posttraumatic	vaccinated (Yes/Unsure/I don't	hyperactivity (23.3%),
					Diseases,	stress disorder	know/Probably would	posttraumatic stress
					Tenth	(PTSD), attention	not/Definitely would not)	(23.1%), bipolar
					Revision	deficit and		(18.0%), generalized
					(ICD-10),	hyperactivity		anxiety (16.5%), major
					obtained	disorder (ADHD),		depressive (16.1%), and
					from medical	alcohol use		other anxiety (15.5%)
					records	disorder (AUD),		disorders, and tobacco
						and substance use		use (18.6%). After
						disorder (SUD).		adjustment for
								sociodemographic
								characteristics and

								physical comorbidities,
								SUD conferred 68%
								higher odds for vaccine
								hesitancy. Bipolar
								disorder was associated
								with 35% lower odds for
								vaccine hesitancy.
								Nicotine
								dependence/tobacco use
								was associated with
								vaccine hesitancy.
Huang et	Mainlan	Survey	Outpatients and	906	Self-reported	Psychotic	"Are you willing to take a	Among 906 participated
al. (2021)	d China		inpatients at a	(male=39%,	clinical	disorders, mood	COVID-19 vaccine?"	patients, 526 (58.1%)
			psychiatric	female=61%	diagnosis	disorders, anxiety	(Yes/No/Unsure)	reported that they were
			speciality hospital	)		disorders, other		willing to take the
						disorders		vaccine, and 282 (31.1%)
								were hesitant to take the
								vaccine (17.1% unwilling
								and 14.0% unsure).

Jefsen	Denmar	Longitudin	Randomly	Mental	Clinical	Not described	"Have you been offered	Vaccine willingness was
(2021)	k	al survey	selected patients	illness	diagnosis		vaccination against	high in both groups, but
			with mental	patients =	obtained		coronavirus? (Yes/No/Do not	slightly lower amongst
			illness from the	992, general	from medical		wish to answer). For those	patients with mental
			psychiatric	Danish	records		answered Yes: "Have you	illness (84.8%),
			services of the	population =			accepted this offer?"	compared with the
			Central Denmark	2458			(Yes/No/Do not wish to	general population
			Region and one				answer). For those answered	(89.5%).
			targeting the				otherwise: "Will you accept	
			general Danish				vaccination against	
			population				coronavirus, once it is offered	
							to you? (Yes/No/Do not wish	
							to answer)	
Khaled	Qatar	Survey	Nationally	1038	Self-reported	moderate-to-	"I am willing to get	The three vaccine
(2021)			representative	(male=67%,	survey: the	severe symptoms	coronavirus vaccine if it	willingness groups
			sample of the	female=33%	Physician	of depression or	became available for me" (5-	(accepting, hesitant,
			population	)	Health	anxiety	point Likert Scale: 1 =	vaccine-resistant)
			recruited from the		Questionnair		Strongly agree, 2 = Somewhat	differed significantly on
			community		e (PHQ-9)		agree, 3 = Neutral, 4 =	the presence of current

	and the 7-	Somewhat disagree, 5 =	anxiety or depression. In
	item	Strongly disagree). Responses	the accepting group, 94%
	Generalized	were collapsed into three	were people without
	Anxiety	groups: vaccine accepting	current anxiety or
	Disorder	(strongly agree), vaccine	depression, 6% were
	Questionnair	resistant or refusers (strongly	people with current
	e (GAD-7)	disagree) and vaccine hesitant	anxiety or depression. In
		(somewhat agree, neutral,	the vaccine hesitant
		somewhat disagree)	group, 90% were people
			without current anxiety
			or depression, 10% were
			people with current
			anxiety or depression. In
			the vaccine-resistant
			group, 86% were people
			without current anxiety
			or depression, 14% were
			people with current
			anxiety or depression.

Mazereel	Belgium	Healthcare	Patients at a	1151	Clinical	Cognitive	Patients' acceptance of the	1070 (93%) patients
et al.		assessment	psychiatric	patients	diagnosis	disorder,	COVID-19 vaccine when	accepted the COVID-19
(2021)			hospital who were	(male=41%,	obtained	psychotic	offered.	vaccine they were
			offered a COVID	female=59%	from medical	disorder, bipolar		offered. Logistic
			vaccine	)	records	disorder,		regression did not show
						depressive		any effect of diagnosis
						disorder,		on vaccination status.
						developmental		This rate was not lower
						disorder, anxiety		than that in the general
						disorder,		population: by July 19,
						personality		2021, 88.9% of the adult
						disorder,		population in the same
						substance use		area had received their
						disorder, eating		first vaccine dose, and
						disorder,		61.6% were fully
						adjustment		vaccinated.
						disorder, etc.		
Nguyen et	US	Longitudin	Nationally	77104 adults	Self-reported	Anxiety and	"Have you received a COVID-	Adults with anxiety or
al. (2022)		al survey	representative	(30% had	survey: the	depression	19 vaccine?" (yes/no) For	depression were more

			sample of the	anxiety	two-item		people who answered no, they	likely to intend to get a
			population	symptoms,	Patient		were asked "Once a vaccine to	vaccine than those
			recruited from the	25% had	Health		prevent COVID-19 is available	without these conditions.
			community	depression	Questionnair		to you, would	
				symptoms,	e (PHQ-2)		youdefinitely/probably/proba	
				35% had	and the two-		bly not/or definitely not get a	
				symptoms of	item		vaccine."	
				either	Generalized			
				disorder)	Anxiety			
					Disorder			
					(GAD-2)			
					scale			
Nishimi et	US	Longitudin	The sample	544	Self-reported	posttraumatic	"Have you received at least	PTSD symptom clusters
al. (2022)		al survey	included	(male=21%,	survey: 20-	stress disorde	one shot of COVID-19	were not associated with
			community-	female=77%	item	(PTSD)	vaccine?" (yes/no) For people	COVID-19 vaccine
			dwelling US	, other=3%)	posttraumati		who answered no, they were	hesitancy in the full
			adults with high		c stress		asked "Once a vaccine to	sample. Total PTSD
			levels of pre-		disorde		prevent COVID-19 is available	symptoms were also not
			pandemic trauma		(PTSD)		to you, would	associated with receiving

			and trauma-		Checklist-5		youdefinitely/probably/not	the COVID-19 vaccine
			related distress		(PCL-5)		sure/probably not/or definitely	or with hesitancy versus
			based on sample				not get a vaccine."	acceptance among
			recruitment.					unvaccinated individuals
								(n = 368), or with odds of
								being unsure versus those
								who would probably or
								definitely not getting
								vaccinated among
								vaccine-hesitant
								individuals (n = 148).
								Increasing PTSD
								symptom severity from
								baseline to follow-up was
								marginally associated
								with higher odds of
								COVID-19 vaccine
								hesitance.
Paul and	UK	Longitudin	Fully vaccinated	22139 adults	Self-reported	Depression,	"How likely do you think you	Having a mental health

Fancourt		al survey	adults recruited	(weighted:	mental health	anxiety, or other	are to get a COVID-19 vaccine	condition was not
(2022)			from the	male=49%,	diagnosis	psychiatric	when one is approved?" (1,	associated with
			community	female=51%	(yes/no)	diagnosis	very unlikely - 6, very likely)	uncertainty or
				)			"How likely do you think you	unwillingness to accept a
							are to get a COVID-19 booster	COVID-19 booster
							vaccine if/when you are	vaccine.
							offered one?" (1, very unlikely	
							- 6, very likely)	
Qin (2022)	Mainlan	Survey	Psychiatric	1328	Clinical	Bipolar disorders,	Not reported	85.5% of patients were
	d China		patients who have	patients	diagnosis	depressive		willing to be vaccinated.
			previously been	(male=34%,	obtained	disorders, anxiety		
			diagnosed with	female=66%	from medical	disorders,		
			bipolar disorders,	)	records	obsessive		
			depressive			compulsive		
			disorders, anxiety			disorders, sleep		
			disorders,			disorders,		
			obsessive			schizophrenia,		
			compulsive			and other mental		
			disorders, sleep			disorders		

			disorders,					
			schizophrenia,					
			and other mental					
			disorders					
Ren et al.	Mainlan	Survey	Psychiatric	229 patients	Clinical	Schizophrenia,	"Would you like to be	77.7% (n=178) of
(2021)	d China		patients who have	and 143	diagnosis	bipolar disorder,	vaccinated if COVID-19	patients and 100% of the
			previously been	family	obtained	major depression	vaccines become available?"	family caregivers said
			diagnosed with	caregivers	from medical	disorder,	(Yes/No)	they intended to receive
			schizophrenia,		records	generalized		vaccination once the
			bipolar disorder,			anxiety disorder		COVID-19 vaccine
			major depression			or other mental		became available on the
			disorder,			disorders		market.
			generalized					
			anxiety disorder					
			or other mental					
			disorders.					
Roberts et	US	Survey	Individuals with	332	Self-reported	Not described	"How willing would you be to	Participants with mental
al. (2022)			mental illness or	individuals	diagnosis of		receive a vaccine [specify the	illness and no illness
			substance use	with mental	mental		stage of vaccine approval]" (1-	responded similarly on

			disorder	illness	illness		7: 1 = "Not at all willing";	willingness to accept a
				(male=47%,	(yes/no)		4 = "Somewhat willing";	COVID-19 vaccine.
				female=52%			7 = "Extremely willing")	
				), 328				
				individuals				
				with no				
				illness				
				(male=64%,				
				female=36%				
				)				
Sekizawa	Japan	Longitudin	Community	11846	Self-reported	Depression,	"Are you going to receive a	46% of participants with
et al.		al survey	sample	(male=50%,	survey:	anxiety	vaccine against COVID-19?"	moderate-to-severe
(2022)				female=50%	Patient		(Willing to be	depression symptoms at
				)	Health		vaccinated/Unwilling to be	wave 1 were willing to
				participants.	Questionnair		vaccinated/Undevided)	accept a vaccine, 38%
				1705	e-9 (PHQ-9),			were undecided, and
				participants	Generalized			13% were unwilling.
				reported	Anxiety			45% of participants with
				moderate-to-	Disorder-7			moderate-to-severe

severe	scale (GAD-	depression symptoms at
depression	7)	wave 3 were willing to
symptoms at		accept a vaccine, 38%
wave 1,		were undecided, 14%
1751		were undecided. 45% of
participants		participants with
reported at		moderate-to-severe
wave 3.		anxiety symptoms at
1021		wave 1 were willing to
participants		accept a vaccine, 38%
reported		were undecided, and
moderate-to-		14% were unwilling.
severe		44% of participants with
anxiety		moderate-to-severe
symptoms at		anxiety symptoms at
wave 1 and		wave 3 were willing to
1057		accept a vaccine, 37%
reported at		were undecided, 16%
wave 3.		were undecided. After

								adjusting for other
								factors, those who were
								moderate-severely
								depressed, and severely
								depressed were more
								likely to be undecided
								than those who were not
								depressed. After
								adjusting for other
								factors, those who were
								mildly depressed at wave
								1, moderately depressed
								at wave 3, and moderate-
								severely anxious at wave
								3 were significantly more
								likely to be unwilling to
								be vaccinated.
Sullivan et	US	Survey	People with	109	Clinical	Opioid use	Participants were asked to	32.1% of the participants
al. (2022)			opioid use	(female=56	diagnosis	disorder (OUD)	select which best described	reported willingness to

			disorder (OUD)	%)	obtained		their COVID-19 vaccination	use a safe and partially
			enrolled in a		from medical		intentions	effective vaccine against
			methadone		records		(Willing/Unwilling/Conditiona	COVID-19. 47.7%
			maintenance				lly willing)	endorsed willingness to
			program					be vaccinated only if safe
								and highly effective.
								20.1% of the participants
								were unwilling to be
								vaccinated in either
								scenario.
Tsai et al.	Taiwan	Survey	Caregivers of	252	Clinical	Attention-	"When a COVID-19 vaccine	Regarding caregivers'
(2022)			children with	caregivers	diagnosis	deficit/hyperactivi	becomes available, will you be	intentions to vaccinate
			Attention-	(male=21%,	obtained	ty disorder	willing to vaccinate your	their children, 91
			deficit/hyperactivi	female=79%	from medical	(ADHD)	child?" (Definitely not	(36.1%) caregivers
			ty disorder	)	records		willing/Not sure/If my doctor	reported the willingness
			(ADHD)				recommends it, I would let my	to let their child take
							children receive it/Definitely	vaccine shots against
							wiling). "Please rate your	COVID-19, 117 (46.4%)
							current willingness to let your	would let their child take

			child receive a COVID-19	vaccine shots under their
			vaccine." (Definitely not	doctors'
			willing/Not sure/If my doctor	recommendation, 40
			recommends it, I would let my	(15.9%) felt hesitant
			children receive it/Definitely	about vaccination, and 4
			wiling)	(1.6%) definitely refused
				to vaccinate their
				children. The proportion
				of caregivers who were
				willing to vaccinate their
				children definitely or
				under doctors'
				recommendation
				increased from 62.8% in
				the first wave of the
				study to 82.5% in the
				second wave of the
				study.

## Table 2 Summary of studies investigating the association between mental health conditions and COVID-19 vaccine uptake

Author	Region	Population	Size	Mental health	Vaccine	Mental health condition	Barrier to	Results
				measure	uptake		vaccine uptake	
					measure			
Balut et	US	Veterans	83528	Self-reported	Electronic	Alcohol use disorder, drug	NA	Veterans with any mental
al.,		experiencin	(male=90%,	mental health	health	use disorder, posttraumatic		health conditions (47.2% vs.
(2021)		g	female=10%)	diagnosis	records	stress disorder, psychotic		38.3%) were more likely to get
		homelessne		(yes/no)		disorders, depression,		vaccinated.
		SS				anxiety, schizophrenia, or		
						bipolar disorder		
Curtis et	UK	All patients	57.9 million	Clinical	Electronic	Severe mental illness	NA	Presence of a severe mental
al.,		registered		diagnosis	health			health condition was associated
(2022)		with a		(yes/no),	records			with lower vaccination rates
		general		obtained from				(71% vs 85% in those without
		practice in		medical records				severe mental health
		England						conditions) and more declines
								(5% vs 3% in those without
								severe mental health

								conditions) being recorded, and
								a similar but less divergent
								pattern was seen in those with a
								learning disability.
Curtis et	UK	All patients	57.9 million	Clinical	Electronic	Severe mental illness	NA	Vaccination coverage was
al.,		registered		diagnosis	health			substantially lower among
(2022)		with a		(yes/no),	records			those living with severe mental
		general		obtained from				illness (89.5%).
		practice in		medical records				
		England						
Gibbon	UK	In-patients	85	Clinical	Survey	Not described	NA	68 (80.0%) consented and 17
et al.,		within a		diagnosis				(20.0%) declined to consent to
(2021)		medical		obtained from				the COVID-19 vaccine.
		secure		medical records				
		psychiatric						
		hospital						
Hassan et	UK	All patients	1152831	Clinical	Electronic	Schizophrenia or related	NA	Compared to matched controls,
al.,		registered	adults with and	diagnosis	health	psychotic disorders, bipolar		vaccination rates were highest
(2022)		with a	without severe	obtained from	records	disorder, and recurrent		among people with recurrent

general	mental illness:	medical records	major depressive disorder,	major depression (77.1%),
practice in	exclusive		and a 10% sample of	followed by bipolar disorder
England	groups of		individuals with diagnoses	(75.7%), other depressive
	individuals		of other depressive	disorders (75.1%), and
	with		disorders, excluding all	psychotic disorders (69.6%).
	schizophrenia		previously mentioned	The prevalence of vaccination
	or related		diagnoses.	among all controls was 68.4%.
	psychotic			The proportion of individuals
	disorders			recorded as having declined
	(N=46,859),			vaccination by June 30, 2021
	bipolar			among all controls was 2.0%.
	disorder			Rates of having been recorded
	(N=3,461),			as declining vaccination were
	and recurrent			significantly higher across all
	major			mental disorders examined,
	depressive			with psychotic disorder
	disorder			diagnoses highest (5.0%),
	(N=134,661),			followed by bipolar disorder
	and a 10%			(3.8%), recurrent major

			sample of					depression (2.9%) and other
			individuals					depressive disorders (2.8%).
			with diagnoses					
			of other					
			depressive					
			disorders,					
			excluding all					
			previously					
			mentioned					
			diagnoses					
			(N=45,586).					
Huang et	Mainland	Outpatients	906	Self-reported	Survey	Psychotic disorders, mood	Compared to	98 (10.8%) patients had taken
al.,	China	and	(male=39%,	clinical		disorders, anxiety	vaccine-	the vaccine at the time of this
(2021)		inpatients	female=61%)	diagnosis		disorders, other disorders	hesitant	survey,
		at a					persons,	
		psychiatric					vaccine-	
		speciality					recipients were	
		hospital					more likely to	
							have a college-	

		level education
		or above, be
		married,
		remarried, or
		cohabiting,
		rate their
		family
		financial status
		as "good",
		agree that the
		preventive
		effect of
		vaccines is
		good, believe
		that at least
		half of
		vaccine-
		recipients
		would be

							immune to	
							COVID-19,	
							believe that	
							vaccines are	
							safe, be not	
							worried about	
							the side effects	
							of vaccines, be	
							outpatients,	
							have mental	
							disorders other	
							than psychotic,	
							mood, and	
							anxiety	
							disorder, and	
							be not	
							depressed	
Mazereel	Belgium	Healthcare	Patients at a	1151 patients	Clinical	Cognitive disorder,	NA	1070 (93%) patients accepted
et al.		assessment	psychiatric	(male=41%,	diagnosis	psychotic disorder, bipolar		the COVID-19 vaccine they

(2021)			hospital who	female=59%)	obtained	disorder, depressive		were offered. Logistic
			were offered a		from medical	disorder, developmental		regression did not show any
			COVID		records	disorder, anxiety disorder,		effect of diagnosis on
			vaccine			personality disorder,		vaccination status. This rate
						substance use disorder,		was not lower than that in the
						eating disorder, adjustment		general population: by July 19,
						disorder, etc.		2021, 88.9% of the adult
								population in the same area had
								received their first vaccine
								dose, and 61.6% were fully
								vaccinated.
Moeller	US	Patients at	174	Clinical	Healthcare	Attention-	NA	29.8% of adolescent inpatients
et al.,		a academic	(male=35%,	diagnosis	assessment	deficit/hyperactivity		with mental illness screened for
(2021)		child and	female=66%)	obtained from		disorder, adjustment		the COVID-19 vaccine
		adolescent		medical records		disorder, anxiety disorder		requested and consented to
		psychiatric				or trauma-related disorder,		vaccination. 30.5% of
		hospital				autism spectrum disorder,		adolescent patients have
						disruptive mood		already received one dose of
						dysregulation disorder,		the vaccine before admission.

						major depressive		This is comparable to the
						disorder/suicidal ideations,		national average on June 30,
						others		2021, with 30.9% of
								adolescents aged 12-15 years
								having at least one dose of the
								vaccine.
Murphy	Northern	Patients	1433814	Prescription of	Electronic	Recipients of anxiolytics,	NA	After adjusting for
et al.,	Ireland	registered	individuals	psychotropic	health	antipsychotics, hypnotics,		sociodemographic,
(2022)		with the	(male=49%,	drugs obtained	records	and antidepressant.		socioeconomic and physical
		Northern	female=51%).	from medical				health factors, individuals in
		Ireland	267 049 (19%)	records				receipt of anxiolytics, on
		National	individuals					antipsychotics and hypnotics
		Health	had received					were less likely to receive the
		Authority	psychotropic					COVID-19 vaccination.
		Informatio	medication in					Antidepressant use was not
		n System	both 3-month					associated with vaccination.
			periods before					
			the vaccination					
			programme					

			started, of					
			which 33%					
			had been					
			prescribed					
			antidepressants					
			, 3% had been					
			prescribed					
			hypnotics and					
			anxiolytics,					
			and 2% had					
			been					
			prescribed					
			antipsychotics.					
Nguyen	US	Nationally	77104 adults	Self-reported	Longitudinal	Anxiety and depression	Among those	A lower proportion of adults
et al.,		representati	(30% had	survey: the two-	survey		who did not	with anxiety (39.9%),
(2022)		ve sample	anxiety	item Patient			get vaccinated	depression (37.7%), and either
		of the	symptoms,	Health			but probably	disorder (40.2%) received at
		population	25% had	Questionnaire			will later,	least 1 dose of the COVID-19
		recruited	depression	(PHQ-2) and the			concerns about	vaccine compared to adults

from the	symptoms,	two-item	side effects	without any symptoms (52.9%).
community	35% had	Generalized	and	Adults with anxiety or
	symptoms of	Anxiety	uncertainty	depression were less likely to
	either	Disorder (GAD-	about whether	receive COVID-19 vaccination
	disorder)	2) scale	the vaccine	than those without these
			will work were	conditions.
			higher among	
			people with	
			anxiety or	
			depressive	
			symptoms than	
			those without	
			any symptoms	
			(56.9%	
			compared to	
			47.1%, and	
			19.6%	
			compared to	
			13.5%,	

			respectively).
			Among those
			who did not
			get vaccinated
			and probably
			will not get
			vaccinated,
			both a lack of
			trust in
			COVID-19
			vaccines and
			in the
			government
			were higher
			among people
			with anxiety or
			depression
			compared to
			people without

		these
		disorders.
		Among people
		who did not
		get vaccinated
		and definitely
		will not get a
		vaccine,
		dislike of
		vaccines was
		higher among
		those with
		anxiety or
		depression
		compared to
		those without
		either disorder
		(24.4%)
		compared to

							16.2%,	
							respectively).	
Nilsson	Denmark	All Danish	4935344	Clinical	Electronic	Substance abuse, supported	NA	The vaccine uptake for people
et al.,		residents	individuals,	diagnosis	health	psychiatric housing,		with psychiatric exposures were
(2022)		being alive	accounting for	obtained from	records	psychiatric hospital		lower than in the nonexposed
		and living	2560981	medical records		admission, and severe		individuals. Among the
		in	person-years			mental illness		psychiatric groups, highest
		Denmark	under			(schizophrenia, bipolar		cumulative vaccine uptake was
		on Dec 27,	observation for			disorder, or depressive		found for severe mental illness
		2020 (i.e.	two doses of			disorder)		and lowest uptake for substance
		first date of	vaccines					abuse.
		vaccination	against SARS-					
		against	CoV-2					
		SARS-	infection.					
		CoV-2						
		infection in						
		Denmark)						
		and aged at						
		least 15						

		years on						
		the day of						
		inclusion.						
Qin et	Mainland	Psychiatric	1328 patients	Clinical	Survey	Bipolar disorders,	Only finishing	69.4% of patients had been
al.,	China	patients	(male=34%,	diagnosis		depressive disorders,	junior middle	vaccinated at the time of the
(2022)		who have	female=66%)	obtained from		anxiety disorders,	school was	survey, which was lower than
		previously		medical records		obsessive compulsive	associated	their family members (89.8%)
		been				disorders, sleep disorders,	with lower	
		diagnosed				schizophrenia, and other	vaccination	
		with				mental disorders	rates compared	
		bipolar					to graduating	
		disorders,					from	
		depressive					universities.	
		disorders,					Patients who	
		anxiety					were willing to	
		disorders,					be vaccinated	
		obsessive					were more	
		compulsive					likely to get	
		disorders,					inoculated	

	sleep					(77.5%) and	
	disorders,					patients who	
	schizophre					were unwilling	
	nia, and					(20.8%) and	
	other					uncertain	
	mental					(12.5%) about	
	disorders					vaccination	
						were less	
						likely to be	
						inoculated	
						compared to	
						those who	
						were	
						indifferent	
						(43.2%) about	
						vaccines.	
Raffard France	Patients	100 patients	Clinical	Survey	Schizophrenia	Non-	A statistical trend was noted
et al.,	with	(female=38%)	diagnosis			vaccinated	with respect to the proportion
(2022)	diagnosis	and 72 family	obtained from			individuals	of vaccinated participants,

of	caregivers	medical records		had higher	showing lower rates of
schizophre	(female=26%)			negative	vaccination in patients (64%),
nia				attitudes	compared to controls (77.8% of
				towards	n=72, p = 0.07, Phi = 0.15).
				vaccine	
				benefit,	
				unforeseen	
				future effects	
				of the vaccine,	
				and	
				commercial	
				profiteering of	
				the vaccine,	
				and had higher	
				preference for	
				natural	
				immunity.	
				Non-	
				vaccinated	

							individuals	
							had lower	
							levels of trust	
							in institutions	
							than did the	
							vaccinated	
							participants.	
Sekizawa	Japan	Communit	11846	Self-reported	Longitudinal	Depression, anxiety	NA	2% of participants with
et al.,		y sample	(male=50%,	survey: Patient	survey			moderate-to-severe depression
(2022)			female=50%)	Health				symptoms at wave 1 were
			participants.	Questionnaire-9				already vaccinated at wave 3,
			1705	(PHQ-9),				3% of participants with
			participants	Generalized				moderate-to-severe depression
			reported	Anxiety				symptoms at wave 3 were
			moderate-to-	Disorder-7 scale				already vaccinated at wave 3.
			severe	(GAD-7)				3% of participants with
			depression					moderate-to-severe anxiety
			symptoms at					symptoms at wave 1 were
			wave 1, 1751					already vaccinated at wave 3,
L								

			participants					3% of participants with
			reported at					moderate-to-severe anxiety
			wave 3. 1021					symptoms at wave 3 were
			participants					already vaccinated at wave 3.
			reported					
			moderate-to-					
			severe anxiety					
			symptoms at					
			wave 1 and					
			1057 reported					
			at wave 3.					
Shkalim	Israel	Adolescent	46511	Clinical	Survey	Attention-	NA	In total, 52.5% of adolescents
Zemer et		s	adolescents	diagnosis		deficit/hyperactivity		with ADHD were vaccinated,
al.,		diagnosed	aged 12-17	obtained from		disorder (ADHD)		compared with 47.8% of
(2022)		with	years (n=8241	medical records				adolescents without ADHD.
		attention-	with ADHD,					1.2% of adolescents with
		deficit/hyp	18%)					ADHD aged 12-15 years
		eractivity						received the booster dose,
		disorder						which was comparable to 1.4%

		(ADHD)						of adolescents with non-ADHD
								aged 16-17 years. A total of
								45.8% of adolescents with
								ADHD aged 16-17 years
								received the booster dose,
								higher than 42.5% of
								adolescents with non-ADHD
								aged 16-17 years.
Tzur	Israel	Patients	4797	Clinical	Electronic	Schizophrenia	NA	20.7% of individuals with
Bitan et		with	individuals	diagnosis	health			schizophrenia were completely
al.,		schizophre	(male=60%)	obtained from	records			unvaccinated, compared with
(2022)		nia	with	medical records				14.5% of matched control
			schizophrenia					participants. Once vaccinated,
			and 34797					no significant differences were
			matched					observed in the uptake of the
			controls					second vaccine. Gaps emerged
			(male=60%)					again with the booster vaccine,
								with 74.7% of individuals with
								schizophrenia completing the

								booster, lower than 77.9% in
								the control group.
Uvais,	India	Patients	62 patients	Clinical	Survey	Bipolar affective disorder,	Respondents	Only 27.9% of the respondents
N.A.,		with severe	(male=69%,	diagnosis		schizophrenia, psychosis,	in the	received the first dose of
(2022)		mental	female=31%)	obtained from		obsessive-compulsive	vaccinated	COVID-19 vaccination, and
		illness		medical records		disorder, depressive	group	59.7% were recommended for
						disorder	perceived the	vaccination from a healthcare
							vaccine to be	provider.
							more effective	
							in preventing	
							COVID-19	
							infection than	
							those in the	
							unvaccinated	
							group.	
							Vaccinated	
							respondents	
							were also less	
							in agreement	

			with the
			statement
			about the risk
			of COVID-19
			vaccine
			worsening
			mental illness.
			Both
			vaccinated and
			unvaccinated
			respondents
			tended to
			disagree with
			the statement
			about COVID-
			19 vaccines
			can cause
			COVID-19
			infection,
			interiori,

		COVID-19
		vaccines can
		cause mental
		illness, or it is
		harmful to take
		COVID-19
		vaccination
		while taking
		medications
		for mental
		illness. Apart
		from age,
		recommendati
		on for
		vaccination
		from health
		care providers
		was
		significantly
		~ ·

			and positively	
			associated	
			with	
			vaccination.	

## Table 3 Summary of studies investigating the association between mental health conditions and COVID-19 vaccine breakthrough

Author	Region	Data source	Population	Size	Mental health	Mental health	Res:breakthrough
					measure	condition	
Nishimi et al.,	US	Electronic	Patients who	263697 patients	Clinical diagnosis	Depressive,	51.4% of the fully vaccinated patients
(2022)		health	accessed Veterans	(male=90.8%)	obtained from	posttraumatic stress,	had at least 1 psychiatric disorder
		records	Affairs (VA) health		medical records	anxiety, adjustment,	diagnosis, and 14.8% developed a
			care during the			alcohol use,	breakthrough infection. A diagnosis of
			study period, had at			substance use,	any psychiatric disorder was associated
			least 1 SARS-CoV-			bipolar, psychotic,	with increased incidence of
			2 test recorded in			attention-deficit/	breakthrough infection, both in models
			the electronic health			hyperactivity,	adjusted for potential confounders and
			record, had no			dissociative, and	additionally adjusted for medical

		record of SARS-			eating disorders.	comorbidities and smoking. Most
		CoV-2 infection				specific psychiatric disorder diagnoses
		prior to vaccination,				were associated with an increased
		and had completed a				incidence of breakthrough infection,
		full SARSCoV-2				with the highest relative risk observed
		vaccination regimen				for adjustment disorder and substance
		14 days or more				use disorders.
		prior.				
Wang et al., US	Electronic	Fully vaccinated	579,372	Clinical diagnosis	Substance use	Among SUD patients, the risk for
(2022)	health	patient with	individuals	obtained from	disorder (SUD)	breakthrough infection ranged from
	records	substance use	(30,183 with a	medical records		6.8% for tobacco use disorder to 7.8%
		disorders (SUD)	diagnosis of			for cannabis use disorder, all
			SUD and			significantly higher than the 3.6% in
			549,189 without			non-SUD population. Breakthrough
			such a			infection risk remained significantly
			diagnosis) who			higher after controlling for
			were fully			demographics (age, gender, ethnicity)
			vaccinated			and vaccine types for all SUD subtypes,
			between			except for tobacco use disorder, and was

	December 2020	highest for cocaine and cannabis use
	and August	disorders. When matching patients with
	2021, and had	SUD and non-SUD individuals for
	not contracted	lifetime comorbidities and adverse
	COVID-19	socioeconomic determinants of health,
	infection prior to	the risk for breakthrough infection no
	vaccination	longer differed between these
		populations, except for patients with
		cannabis use disorder, who remained at
		increased risk. The risk for breakthrough
		infection was higher in SUD patients
		who received the Pfizer than the
		Moderna vaccine. In the vaccinated SUD
		population, individuals with
		breakthrough infections had higher risk
		for hospitalisation and death, compared
		to non-breakthrough infections.

## References

- Abramovich, A., Pang, N., Kunasekaran, S., Moss, A., Kiran, T., & Pinto, A. D. (2022).
  Examining COVID-19 vaccine uptake and attitudes among 2SLGBTQ+ youth experiencing homelessness. *BMC Public Health*, 22(1), 122.
  https://doi.org/10.1186/s12889-022-12537-x
- Afifi, T. O., Salmon, S., Taillieu, T., Stewart-Tufescu, A., Fortier, J., & Driedger, S. M.
  (2021). Older adolescents and young adults willingness to receive the COVID-19
  vaccine: Implications for informing public health strategies. *Vaccine*, *39*(26), 3473–3479.
- Ajzen, I., & Manstead, A. (2007). Changing health-related behaviours: An approach based on the theory of planned behaviour. In *The Scope of Social Psychology*. Psychology Press.
- Armitage, C. J., & Conner, M. (2001). Efficacy of the Theory of Planned Behaviour: A metaanalytic review. *British Journal of Social Psychology*, 40(4), 471–499. https://doi.org/10.1348/014466601164939

Authority of the House of Commons. (2022). Roll out of the COVID-19 vaccine programme.

- Ayling, K., Jia, R., Coupland, C., Chalder, T., Massey, A., Broadbent, E., & Vedhara, K.
  (2022). Psychological Predictors of Self-reported COVID-19 Outcomes: Results
  From a Prospective Cohort Study. *Annals of Behavioral Medicine*, *56*(5), 484–497.
  https://doi.org/10.1093/abm/kaab106
- Bai, W., Cai, H., Jin, Y., Zhang, Q., Cheung, T., Su, Z., Tang, Y.-L., Ng, C. H., & Xiang, Y.-T. (2021). COVID-19 vaccine hesitancy in community-dwelling and hospitalized patients with severe mental illness. *Psychological Medicine*, 1–3.

- Balut, M. D., Chu, K., Gin, J. L., Dobalian, A., & Der-Martirosian, C. (2021). Predictors of COVID-19 Vaccination among Veterans Experiencing Homelessness. *101629355*, 9(11).
- Birhane, M., Bressler, S., Chang, G., Clark, T., Dorough, L., Fischer, M., Watkins, L. F.,
  Goldstein, J. M., Kugeler, K., Langley, G., Lecy, K., Martin, S., Medalla, F., Mitruka,
  K., Nolen, L., Sadigh, K., Spratling, R., Thompson, G., & Trujillo, A. (2021).
  COVID-19 Vaccine Breakthrough Infections Reported to CDC United States,
  January 1–April 30, 2021. *Morbidity and Mortality Weekly Report*, 70(21), 792–793.
  https://doi.org/10.15585/mmwr.mm7021e3
- Blevins, C. A., Weathers, F. W., Davis, M. T., Witte, T. K., & Domino, J. L. (2015). The
  Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial
  Psychometric Evaluation. *Journal of Traumatic Stress*, 28(6), 489–498.
  https://doi.org/10.1002/jts.22059
- Cai, H., Bai, W., Du, X., Zhang, L., Zhang, L., Li, Y.-C., Liu, H.-Z., Tang, Y.-L., Jackson, T., Cheung, T., An, F.-R., & Xiang, Y.-T. (2022). COVID-19 vaccine acceptance and perceived stigma in patients with depression: A network perspective. *Transl Psychiatry Psychiatry*, 12(1), 429.
- Cohen, S. (2021). Psychosocial Vulnerabilities to Upper Respiratory Infectious Illness: Implications for Susceptibility to Coronavirus Disease 2019 (COVID-19).
   *Perspectives on Psychological Science*, *16*(1), 161–174.
   https://doi.org/10.1177/1745691620942516
- Cohen, S., Doyle, W. J., Skoner, D. P., Rabin, B. S., Gwaltney, J. M., &
  VirginiaHealthSciencesCenter, U. (1998). *Types of Stressors That Increase* Susceptibility to the Common Cold in Healthy Adults. 17(3), 10.

Cohen, S., Tyrrell, D. A. J., & Smith, A. P. (1991). Psychological Stress and Susceptibility to the Common Cold. *New England Journal of Medicine*, 325(9), 606–612. https://doi.org/10.1056/NEJM199108293250903

Curtis, H. J., Inglesby, P., MacKenna, B., Croker, R., Hulme, W. J., Rentsch, C. T., Bhaskaran, K., Mathur, R., Morton, C. E., Bacon, S. C., Smith, R. M., Evans, D., Mehrkar, A., Tomlinson, L., Walker, A. J., Bates, C., Hickman, G., Ward, T., Morley, J., ... Goldacre, B. (2022). Recording of 'COVID-19 vaccine declined': A cohort study on 57.9 million National Health Service patients' records in situ using OpenSAFELY, England, 8 December 2020 to 25 May 2021. *Eurosurveillance*, 27(33), 2100885. https://doi.org/10.2807/1560-7917.ES.2022.27.33.2100885

- Curtis, H. J., Inglesby, P., Morton, C. E., MacKenna, B., Green, A., Hulme, W., Walker, A. J., Morley, J., Mehrkar, A., Bacon, S., Hickman, G., Bates, C., Croker, R., Evans, D., Ward, T., Cockburn, J., Davy, S., Bhaskaran, K., Schultze, A., ... Collaborative), (The OpenSAFELY. (2022). Trends and clinical characteristics of COVID-19 vaccine recipients: A federated analysis of 57.9 million patients' primary care records in situ using OpenSAFELY. *British Journal of General Practice*, *72*(714), e51–e62.
- Dvorsky, M. R., Breaux, R., Langberg, J. M., & Becker, S. P. (2022). Adolescents with ADHD are at increased risk for COVID-19 vaccine hesitancy. *Journal of Psychiatric Research*, *152*, 25–30. https://doi.org/10.1016/j.jpsychires.2022.06.005
- Eyllon, M., Dang, A. P., Barnes, J. B., Buresh, J., Peloquin, G. D., Hogan, A. C., Shimotsu,
  S. T., Sama, S. R., & Nordberg, S. S. (2022). Associations between psychiatric morbidity and COVID-19 vaccine hesitancy: An analysis of electronic health records and patient survey. *Psychiatry Research*, 307, 114329. https://doi.org/10.1016/j.psychres.2021.114329

- Farcas, A., Christi, P., Fagen, J., & Iftene, F. (2022). Possible predictors of Covid-19 vaccine hesitancy in the psychiatric population—A scoping review. [Review]. *Psychiatry Research Communications*, 2(4), 100075.
- Galanis, P., Vraka, I., Siskou, O., Konstantakopoulou, O., Katsiroumpa, A., & Kaitelidou, D. (2021). Predictors of COVID-19 vaccination uptake and reasons for decline of vaccination: A systematic review [Preprint]. Public and Global Health. https://doi.org/10.1101/2021.07.28.21261261
- Gallagher, S., Phillips, A. C., Ferraro, A. J., Drayson, M. T., & Carroll, D. (2008). Social support is positively associated with the immunoglobulin M response to vaccination with pneumococcal polysaccharides. *Biological Psychology*, 78(2), 211–215. https://doi.org/10.1016/j.biopsycho.2008.01.001
- Gibbon, S., McPhail, E., Mills, G., McBride, M., Storer, R., Taylor, N., & McCarthy, L.
  (2021). Uptake of COVID-19 vaccination in a medium secure psychiatric hospital population. *BJPsych Open*, 7(4), e108. https://doi.org/10.1192/bjo.2021.924
- Hassan, L., Sawyer, C., Peek, N., Lovell, K., Carvalho, A. F., Solmi, M., Tilston, G., Sperrin, M., & Firth, J. (2022). COVID-19 vaccination uptake in people with severe mental illness: A UK-based cohort study. *World Psychiatry*, 21(1), 153–154.
- Huang, H., Zhu, X.-M., Liang, P.-W., Fang, Z.-M., Luo, W., Ma, Y.-M., Zhong, B.-L., & Chiu, H. F.-K. (2021). COVID-19 Vaccine Uptake, Acceptance, and Hesitancy Among Persons With Mental Disorders During the Second Stage of China's Nationwide Vaccine Rollout. *Frontiers in Medicine*, 761601.
- Jefsen, O. H., Kolbaek, P., Gil, Y., Speed, M., Dinesen, P. T., Sonderskov, K. M., & Ostergaard, S. D. (2021). COVID-19 vaccine willingness amongst patients with mental illness compared with the general population. *Acta Neuropsychiatrica*, 33(5), 273–276.

Johnson, T., & Fendrich, M. (2005). Modeling Sources of Self-report Bias in a Survey of Drug Use Epidemiology. Annals of Epidemiology, 15(5), 381–389. https://doi.org/10.1016/j.annepidem.2004.09.004

Juraskova, I., O'Brien, M., Mullan, B., Bari, R., Laidsaar-Powell, R., & McCaffery, K. (2012). HPV Vaccination and the Effect of Information Framing on Intentions and Behaviour: An Application of the Theory of Planned Behaviour and Moral Norm. *International Journal of Behavioral Medicine*, *19*(4), 518–525. https://doi.org/10.1007/s12529-011-9182-5

Kafadar, A. H., Tekeli, G. G., Jones, K. A., Stephan, B., & Dening, T. (2022). Determinants for COVID-19 vaccine hesitancy in the general population: A systematic review of reviews. *Zeitschrift Fur Gesundheitswissenschaften = Journal of Public Health*, 1–17. https://doi.org/10.1007/s10389-022-01753-9

Khaled, S. M., Petcu, C., Bader, L., Amro, I., Al-Hamadi, A. M. H. A., Al Assi, M., Ali, A. A. M., Le Trung, K., Diop, A., Bellaj, T., Al-Thani, M. H., Woodruff, P. W., Alabdulla, M., & Haddad, P. M. (2021). Prevalence and Potential Determinants of COVID-19 Vaccine Hesitancy and Resistance in Qatar: Results from a Nationally Representative Survey of Qatari Nationals and Migrants between December 2020 and January 2021. *Vaccines*, 9(5). https://doi.org/10.3390/vaccines9050471

- Kroenke, K., Spitzer, R. L., Williams, J. B. W., & Löwe, B. (2010). The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: A systematic review. *General Hospital Psychiatry*, 32(4), 345–359. https://doi.org/10.1016/j.genhosppsych.2010.03.006
- Lim, C., Van Alphen, M. U., Maclaurin, S., Mulligan, C., Macri, B., Cather, C., & Freudenreich, O. (2022). Increasing COVID-19 Vaccination Rates Among Patients

With Serious Mental Illness: A Pilot Intervention Study. *Psychiatric Services* (*Washington, D.C.*), 73(11), 1274–1277. https://doi.org/10.1176/appi.ps.202100702

Lord, O., Malone, D., & Mitchell, A. J. (2010). Receipt of preventive medical care and medical screening for patients with mental illness: A comparative analysis. *General Hospital Psychiatry*, 32(5), 519–543.

https://doi.org/10.1016/j.genhosppsych.2010.04.004

- MacDonald, N. E. (2015). Vaccine hesitancy: Definition, scope and determinants. *Vaccine*, *33*(34), 4161–4164. https://doi.org/10.1016/j.vaccine.2015.04.036
- Majeed, A., Pollock, K., Hodes, S., & Papaluca, M. (2022). Implementation of covid-19 vaccination in the United Kingdom. *BMJ*, *378*, e070344. https://doi.org/10.1136/bmj-2022-070344
- Mazereel, V., Vanbrabant, T., Desplenter, F., & De Hert, M. (2021). COVID-19 vaccine uptake in patients with psychiatric disorders admitted to or residing in a university psychiatric hospital. *The Lancet. Psychiatry*, 8(10), 860–861. https://doi.org/10.1016/S2215-0366(21)00301-1
- Moeller, K. E., Meeks, M., Reynoldson, J., & Douglass, M. (2021). Implementation and outcomes of COVID-19 vaccinations at a child and adolescent psychiatric hospital. *Journal of the American Academy of Child & Adolescent Psychiatry*, 60(11), 1332– 1334.
- Murphy, S., O'Reilly, D., Owen, R. K., Akbari, A., Lowthian, E., Bedston, S., Torabi, F., Beggs, J., Chuter, A., de Lusignan, S., Hobbs, R., Robertson, C., Katikireddi, S. V., Sheikh, A., & Bradley, D. T. (2022). Variations in COVID-19 vaccination uptake among people in receipt of psychotropic drugs: Cross-sectional analysis of a national population-based prospective cohort. *British Journal of Psychiatry*, 221(1), 417–424.

Nguyen, K. H., Chen, S., Morris, K., Chui, K., & Allen, J. D. (2022). Mental health symptoms and association with COVID-19 vaccination receipt and intention to vaccinate among adults, United States. *Preventive Medicine: An International Journal Devoted to Practice and Theory*.

Nilsson, S. F., Laursen, T. M., Osler, M., Hjorthøj, C., Benros, M. E., Ethelberg, S., Mølbak, K., & Nordentoft, M. (2022). Vaccination against SARS-CoV-2 infection among vulnerable and marginalised population groups in Denmark: A nationwide population-based study. *The Lancet Regional Health. Europe*, *16*, 100355. https://doi.org/10.1016/j.lanepe.2022.100355

- Nishimi, K., Borsari, B., Tripp, P., Jiha, A., Dolsen, E. A., Woolley, J. D., Neylan, T. C., & O'Donovan, A. (2022). Prior trauma exposure, posttraumatic stress symptoms, and COVID-19 vaccine hesitancy. *Journal of Psychiatric Research*, *151*, 399–404. https://doi.org/10.1016/j.jpsychires.2022.05.003
- Nishimi, K., Neylan, T. C., Bertenthal, D., Seal, K. H., & O'Donovan, A. (2022). Association of Psychiatric Disorders With Incidence of SARS-CoV-2 Breakthrough Infection Among Vaccinated Adults. *JAMA Network Open*, 5(4), e227287.
  https://doi.org/10.1001/jamanetworkopen.2022.7287
- O'Connor, D. B., Thayer, J. F., & Vedhara, K. (2021). Stress and Health: A Review of Psychobiological Processes. *Annual Review of Psychology*, 72(1), 663–688. https://doi.org/10.1146/annurev-psych-062520-122331

Paul, E., & Fancourt, D. (2022). Predictors of uncertainty and unwillingness to receive the COVID-19 booster vaccine: An observational study of 22,139 fully vaccinated adults in the UK. *The Lancet Regional Health. Europe*, *14*, 100317. https://doi.org/10.1016/j.lanepe.2022.100317

- Payberah, E., Payberah, D., Sarangi, A., & Gude, J. (2022). COVID-19 vaccine hesitancy in patients with mental illness: Strategies to overcome barriers-a review. [Review]. *Journal of the Egyptian Public Health Association*, 5.
- Phillips, A. C., Carroll, D., Burns, V. E., Ring, C., Macleod, J., & Drayson, M. (2006). Bereavement and marriage are associated with antibody response to influenza vaccination in the elderly. *Brain, Behavior, and Immunity*, 20(3), 279–289. https://doi.org/10.1016/j.bbi.2005.08.003
- Qin, Y., Zhao, Z., Teng, Z., Xu, B., Wang, X., Guo, J., Huang, J., & Wu, H. (2022). COVID-19 vaccination coverage among patients with psychiatric disorders in China during the pandemic: A cross-sectional study. *BMC Psychiatry*, 22(1), 659. https://doi.org/10.1186/s12888-022-04271-w
- Raffard, S., Bayard, S., Eisenblaetter, M., Attal, J., Andrieu, C., Chereau, I., Fond, G.,
  Leignier, S., Mallet, J., Tattard, P., Urbach, M., Misdrahi, D., Laraki, Y., &
  Capdevielle, D. (2022). Attitudes towards Vaccines, Intent to Vaccinate and the
  Relationship with COVID-19 Vaccination Rates in Individuals with Schizophrenia. *Vaccines*, *10*(8). https://doi.org/10.3390/vaccines10081228
- Ren, X., Shen, F., Gui, Y., Wang, W., Xing, B., & Huang, W. (2021). The attitudes of psychiatric patients towards COVID-19 vaccination in China: A cross-sectional study. *BMC Psychiatry*, 21(1), 475. https://doi.org/10.1186/s12888-021-03484-9
- Rhodes, R. E., & de Bruijn, G.-J. (2013). How big is the physical activity intention– behaviour gap? A meta-analysis using the action control framework. *British Journal* of Health Psychology, 18(2), 296–309. https://doi.org/10.1111/bjhp.12032
- Roberts, L. W., Kim, J. P., Rostami, M., Kasun, M., & Kim, B. (2022). Self-reported influences on willingness to receive COVID-19 vaccines among physically ill, mentally ill, and healthy individuals. *Journal of Psychiatric Research*, 501–510.

- Sage Working Group on Vaccine Hesitanc. (2014). Report of the Sage Working Group on Vaccine Hesitancy. *Organization WH*.
- Sekizawa, Y., Hashimoto, S., Denda, K., Ochi, S., & So, M. (2022). Association between COVID-19 vaccine hesitancy and generalized trust, depression, generalized anxiety, and fear of COVID-19. *BMC Public Health*, 22(1), 126.
- Shkalim Zemer, V., Hoshen, M., Gerstein, M., Richenberg, Y., Jacobson, E., Grossu, R.,
  Cohen, M., & Cohen, H. A. (2022). COVID-19 Vaccine Compliance in Adolescents
  With Attention-Deficit/Hyperactivity Disorder. *International Journal of Psychiatry in Medicine*, 912174221116734. https://doi.org/10.1177/00912174221116734
- Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092. https://doi.org/10.1001/archinte.166.10.1092
- Sullivan, M. C., Mistler, C., Copenhaver, M. M., Wickersham, J. A., Ni, Z., Kim, R. S., & Shrestha, R. (2022). Race, trust, and COVID-19 vaccine hesitancy in people with opioid use disorder. *Health Psychology* : Official Journal of the Division of Health Psychology, American Psychological Association, 41(2), 115–120. https://doi.org/10.1037/hea0001120
- Terry, E., Cartledge, S., Damery, S., & Greenfield, S. (2022). Factors associated with COVID-19 vaccine intentions during the COVID-19 pandemic; a systematic review and meta-analysis of cross-sectional studies. *BMC Public Health*, 22(1), 1667. https://doi.org/10.1186/s12889-022-14029-4
- Thompson, E. J., Williams, D. M., Walker, A. J., Mitchell, R. E., Niedzwiedz, C. L., Yang, T. C., Huggins, C. F., Kwong, A. S. F., Silverwood, R. J., Di Gessa, G., Bowyer, R. C. E., Northstone, K., Hou, B., Green, M. J., Dodgeon, B., Doores, K. J., Duncan, E. L., Williams, F. M. K., Steptoe, A., ... Steves, C. J. (2022). Long COVID burden and

risk factors in 10 UK longitudinal studies and electronic health records. *Nature Communications*, *13*(1), Article 1. https://doi.org/10.1038/s41467-022-30836-0

- Tsai, C.-S., Wang, L.-J., Hsiao, R. C., & Yen, C.-F. (2022). Second Wave of the Study of Taiwanese Caregivers of Children with ADHD in the COVID-19 Pandemic: Intentions to Vaccinate Their Children for COVID-19, and Related Factors. *Vaccines*, *10*(5). https://doi.org/10.3390/vaccines10050753
- Tzur Bitan, D., Kridin, K., Givon-Lavi, N., Krieger, I., Kaliner, E., Cohen, A. D., &
  Weinstein, O. (2022). COVID-19 Booster Vaccination Among Individuals With Schizophrenia in Israel. *JAMA Psychiatry*, 79(5), 508–512.
  https://doi.org/10.1001/jamapsychiatry.2022.0382
- Uvais, N. A. (2022). Factors Associated With COVID-19 Vaccination Uptake Among Community-Dwelling Patients With Severe Mental Illness: A Cross-Sectional Study. *The Primary Care Companion to CNS Disorders*, 24(3).
- Vedhara, K., Cox, N. K., Wilcock, G. K., Perks, P., Hunt, M., Anderson, S., Lightman, S. L., & Shanks, N. M. (1999). Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination. *The Lancet*, 353(9153), 627–631. https://doi.org/10.1016/S0140-6736(98)06098-X
- Wang, L., Wang, Q., Davis, P. B., Volkow, N. D., & Xu, R. (2022). Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry : Official Journal of the World Psychiatric Association (WPA), 21(1), 124–132. https://doi.org/10.1002/wps.20921
- Wang, Q., Yang, L., Jin, H., & Lin, L. (2021). Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors. *Preventive Medicine*, 150, 106694. https://doi.org/10.1016/j.ypmed.2021.106694

- Warren, N., Kisely, S., & Siskind, D. (2021). Maximizing the Uptake of a COVID-19
  Vaccine in People With Severe Mental Illness: A Public Health Priority. *JAMA Psychiatry*, 78(6), 589–590.
- WHO. (n.d.). WHO Coronavirus (COVID-19) Dashboard. Retrieved 24 May 2023, from https://covid19.who.int/
- Yang, H., Chen, W., Hu, Y., Chen, Y., Zeng, Y., Sun, Y., Ying, Z., He, J., Qu, Y., Lu, D.,
  Fang, F., Valdimarsdóttir, U. A., & Song, H. (2020). Pre-pandemic psychiatric
  disorders and risk of COVID-19: A UK Biobank cohort analysis. *The Lancet Healthy Longevity*, 1(2), e69–e79. https://doi.org/10.1016/S2666-7568(20)30013-1